Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: An Italian observational multicenter retrospective study in daily clinical practice

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1671-1676

  Zinzani, Pier Luigi ^a   Rigacci, Luigi ^b   Cox, Maria Cristina ^c   Devizzi, Liliana ^d   Fabbri, Alberto ^e   Zaccaria, Alfonso ^f   Zaja, Francesco ^g   Di Rocco, Alice ^c   Rossi, Giuseppe ^h   Storti, Sergio ⁱ   Fattori, Pier Paolo ^j   Argnani, Lisa ^a   Tura, Sante ^a   Vitolo, Umberto ^k  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

^f SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^g AOUD S M Misericordia   (Italy)

^h SPEDALI CIVILI   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^k CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

more..

Author keywords

Lenalidomide; Non Hodgkin lymphoma; Off label; Refractory; Relapsed

Indexed keywords

LENALIDOMIDE; RITUXIMAB; IMMUNOLOGIC FACTOR; THALIDOMIDE;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INFUSION RELATED REACTION; ITALY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MONOTHERAPY; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OFF LABEL DRUG USE; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; ITALY; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OFF-LABEL USE; RETROSPECTIVE STUDIES; SURVIVAL RATE; THALIDOMIDE;

EID: 84932098487     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.964702     Document Type: Article

References (32)

1. Lu L, Payvandi F, Wu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009; 77: 78-86.
2. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140: 36-45.
3. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002; 99: 4525-4530.
4. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF- Alpha. J Immunol 1999; 163: 380-386.
5. Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharm Exp Th er 2003; 305: 1222-1232.
6. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005; 128: 192-203.
7. Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117: 1605-1613.
8. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58: 1033-1045.
9. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345-1350.
10. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326-2335.
11. Zhu Y X, Braggio E, Shi C X, et al. C ereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779.
12. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.
13. Ramsay A G, Clear A J, Kelly G, et al. F ollicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114: 4713-4720.
14. Zhang L-H, Schafer PH, Muller G, Stirling D, Bartlett B. Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-Hodgkin lymphoma cells are associated with increased SPARC expression. Blood 2008; 112(Suppl.1): Abstract 2612.
15. Qian Z, Zhang L, Cai Z, et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 2011; 35: 380-386.
16. Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 tumor cells. Clin Cancer Res 2008; 14: 4650-4657.
17. Witzig T E, Wiernik P H, Moore T, et al. L enalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin' s Lymphoma. J Clin Oncol 2009; 27: 5404-5409.
18. Wiernik P H, Lossos I S, Tuscano J M, et al. L enalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin ' s lymphoma. J Clin Oncol 2008; 26: 4952-4957.
19. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single- Agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin' s lymphoma. Ann Oncol 2011; 22: 1622-1627.
20. Goy A, Sinha R, Williams ME, et al. Single- Agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib:phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688-3695.
21. Dutia M, Deroock I, Reed-Pease C, et al. L enalidomide plus rituximab leads to a high rate of durable responses in patients with relapsed/refractory indolent non-hodgkin ' s lymphoma Ann Oncol 2011; 22(Suppl. 4): iv183-iv189. Abstract 306.
22. Leonard J, Jung S-H, Johnson JL, et al. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol 2012; 30(Suppl.): Abstract 8000.
23. Wang M, Fayad L, Wagner-Bartak N, et al. L enalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723.
24. Wang M, Fowler N, Wagner-Bartak N, et al. O ral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial. Leukemia 2013; 27: 1902-1909.
25. Zinzani PL, Pellegrini C, GandolfiL, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 trial. Clin Lymphoma Myeloma Leuk 2011; 11: 462-466.
26. Ahmadi T, Chong E A, Gordon A, et al. C ombined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer 2014; 120: 222-228.
27. Chong E A, A hmadi T, A qui N A, et al. H igh response rate to combination lenalidomide-rituximab In Fc RIIIa-F carriers with indolent or mantle cell lymphomas previously refractory to rituximab. Paper presented at: 55th ASH Annual Meeting, 7-10 December 2013, New Orleans, LA.
28. Cai Q, Chen Y, Zou D, et al. N ovel combination of lenalidomiderituximab provides an effective bridge to stem cell transplantation in relapsed and/or refractory aggressive B-cell non-Hodgkin ' s lymphomas: A single center experience. Blood 2013; 122(Suppl. 1): Abstract 3056.
29. Mart ín A, Redondo AM, Ló pez-Guillermo A, et al. Lenalidomide in combination with R-ESHAP (LR-ESHAP) in patients with relapsed or refractory diffuse large B-cell lymphoma candidates to autologous stem-cell transplantation: A phase 1b study from Spanish Group Geltamo. Blood 2013; 122(Suppl. 1): Abstract 4391.
30. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin ' s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
31. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 117: 5058-5066.
32. Eve H E, Carey S, Richardson S J, et al. S ingle- Agent lenalidomide in relapsed/refractory mantle cell lymphoma:results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012; 159: 154-163.